Marinus Pharmaceuticals's long-term debt is $42M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2024), MRNS shows a long-term debt of $42M. That compares with $66M in the prior-year period — down 36.6% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, MRNS's long-term debt is now $42M (was $66M) — a 36.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Marinus Pharmaceuticals is outperforming or lagging.
Tracking MRNS's long-term debt over time shows whether Marinus Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $42M That compares with $66M in the prior-year period — down 36.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Marinus Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $42M) with ownership activity and broader fundamentals.
Marinus Pharmaceuticals's long-term debt is $42M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.